
Opinion|Videos|December 20, 2024
A 60-Year-Old Man With Early Relapse Multiple Myeloma
Author(s)Aimee Merino, MD
Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple myeloma, involving chimeric antigen receptor (CAR) T-cell therapy, aligns with the goals of therapy while exploring alternative treatment options and considerations for high-risk patients.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please share your impressions of the patient case and goals of therapy.
- Do you agree with the treatment decision, why or why not?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































